VASCULITIS SYNDROMES RAVE about rituximab in ANCA vasculitis?

被引：1
|
作者：
Tarzi, Ruth [1 ]
Pusey, Charles [1 ]
机构：
[1] Hammersmith Hosp, Dept Med, Renal & Vasc Inflammat Sect, London W12 0NN, England
来源：
NATURE REVIEWS NEPHROLOGY | 2013年 / 9卷 / 11期
关键词：
ANTIBODY-ASSOCIATED VASCULITIS; WEGENERS-GRANULOMATOSIS; CYCLOPHOSPHAMIDE; REMISSION; INDUCTION; EFFICACY; THERAPY;
D O I：
10.1038/nrneph.2013.204
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Follow-up data from the RAVE trial have shown that rituximab is as effective as immunosuppression with cyclophosphamide followed by azathioprine in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. Rituximab is likely to become the standard of care for many patients with ANCA disease. However, an individualized approach is needed to identify those who require more-intense or prolonged therapy.
引用
收藏
页码：628 / 629
页数：2
相关论文
共 50 条
  • [11] ANCA-associated vasculitis
    Yates, Max
    Watts, Richard
    CLINICAL MEDICINE, 2017, 17 (01) : 60 - 64
  • [12] Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab?
    Tesar, Vladimir
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30 (07) : 1088 - 1090
  • [13] ANCA Vasculitis Recurrence in Hemodialysis Patients: The Role of Rituximab
    Oliveira, Joao
    Bernardo, Joao
    Fonseca, Jose
    Marques, Filipe
    Gameiro, Joana
    Outerelo, Cristina
    Jorge, Sofia
    NEPHRON, 2021, 145 (06) : 711 - 716
  • [14] Extending the Indications for Rituximab in ANCA-Associated Vasculitis
    Jayne, David
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) : 1839 - 1840
  • [15] Rituximab for ANCA-associated vasculitis: The UK experience
    Jayne, David
    PRESSE MEDICALE, 2013, 42 (04): : 532 - 534
  • [16] Severe infections in patients with ANCA-associated vasculitis treated with rituximab
    Segelmark, Leo
    Flores-Suarez, Luis
    Mohammad, Aladdin
    RHEUMATOLOGY, 2022, 61 (01) : 205 - 212
  • [17] Rituximab to treat ANCA-associated vasculitis
    Guillevin, L.
    Mahr, A.
    REVUE DE MEDECINE INTERNE, 2011, 32 (10): : 591 - 593
  • [18] Rituximab treatment of ANCA-associated vasculitis
    Raffray, Loic
    Guillevin, Loic
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (08) : 899 - 910
  • [19] Peripheral neuropathy in ANCA-associated vasculitis: outcomes from the European Vasculitis Study Group trials
    Suppiah, Ravi
    Hadden, Robert D. M.
    Batra, Rajbir
    Arden, Nigel K.
    Collins, Michael P.
    Guillevin, Loic
    Jayne, David R. W.
    Luqmani, Raashid A.
    RHEUMATOLOGY, 2011, 50 (12) : 2214 - 2222
  • [20] Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
    Guillevin, L.
    Pagnoux, C.
    Karras, A.
    Khouatra, C.
    Aumaitre, O.
    Cohen, P.
    Maurier, F.
    Decaux, O.
    Ninet, J.
    Gobert, P.
    Quemeneur, T.
    Blanchard-Delaunay, C.
    Godmer, P.
    Puechal, X.
    Carron, P. -L.
    Hatron, P. -Y.
    Limal, N.
    Hamidou, M.
    Ducret, M.
    Daugas, E.
    Papo, T.
    Bonnotte, B.
    Mahr, A.
    Ravaud, P.
    Mouthon, L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (19) : 1771 - 1780
12345